Skip to main content
Ascelia Pharma logo

Ascelia Pharma — Investor Relations & Filings

Ticker · ACE ISIN · SE0010573113 LEI · 5493002YR9VCJJPWYN08 ST Manufacturing
Open in API
Filings indexed 295 across all filing types
Latest filing 2024-11-29 Declaration of Voting R…
Country SE Sweden
Listing ST ACE

About Ascelia Pharma

https://www.ascelia.com/

Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.

Recent filings

Filing Released Lang Actions
Change in Number of Shares and Votes in Ascelia Pharma AB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly details a 'Change in Number of Shares and Votes' due to the conversion of series C shares into ordinary shares related to a performance-based share saving program. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). Although it is a short announcement, the core content is the capital change itself, not just an announcement of a separate report, making SHA a better fit than RPA or RNS. The document confirms the final share count as of the reporting date.
2024-11-29 English
Ändring av antalet aktier och röster i Ascelia Pharma AB
Share Issue/Capital Change Classification · 95% confidence The document explicitly states 'Ändring av antalet aktier och röster i Ascelia Pharma AB' (Change in the number of shares and votes in Ascelia Pharma AB) and details the resulting total number of shares and votes as of November 29, 2024. This type of announcement, concerning changes in the total share capital structure or voting rights due to internal corporate actions (like converting C-shares to common shares for an employee program), fits best under 'Share Issue/Capital Change' (SHA) or potentially 'Regulatory Filings' (RNS) if it were a general notice. However, since it directly reports a change in the total number of shares and votes, SHA is the most specific fit, as it relates to capital structure changes. It is not a dividend notice (DIV), director dealing (DIRS), or a major shareholding notification (MRQ) which concerns external investors crossing thresholds. Given the context of capital structure modification, SHA is the primary classification.
2024-11-29 Swedish
Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program
Share Issue/Capital Change Classification · 98% confidence The document announces a resolution by the board of directors to convert series C shares into ordinary shares for participants in a long-term incentive program (LTI 2021). This action directly impacts the company's capital structure and share count. This type of announcement, dealing with the issuance or change in the number of shares, aligns best with the 'Share Issue/Capital Change' category (SHA). It is not a general earnings release (ER), a full annual report (10-K), or a simple dividend notice (DIV). Since it is a specific corporate action regarding share capital, SHA is the most precise fit.
2024-11-22 English
Ascelia Pharma beslutar om omvandling av C-aktier till stamaktier för leverans till deltagare i incitamentsprogram
Share Issue/Capital Change Classification · 95% confidence The document announces a decision by the Board of Directors of Ascelia Pharma to convert 26,310 C-shares into common shares for delivery to participants in an incentive program (LTI 2021). This action directly relates to the company's capital structure, specifically the issuance of shares as part of an employee compensation/incentive scheme. This falls under the definition of 'Share Issue/Capital Change' (SHA), as it alters the number and type of outstanding shares. Although it involves an incentive program, the core action is a share issuance/change, making SHA more specific than a general regulatory filing (RNS) or a management announcement (MANG). The document is short and appears to be a formal regulatory announcement of this specific corporate action.
2024-11-22 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport 9M 2024' (Interim Report 9M 2024) and covers the period from January to September 2024. It contains detailed financial tables (income statement, cash flow, liquidity), management commentary (VD-ord), and operational updates. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2024
2024-11-07 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report 9M 2024' and covers the period from January to September 2024. It contains detailed financial tables (Key Ratios Group), a CEO statement, and operational updates. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2024
2024-11-07 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.